Health & Medicine

First Tau-Targeting Drug Slows Alzheimer's Decline by 26% in Landmark Phase 2 Trial

Presented at the Alzheimer's Association International Conference 2026 in London, Biogen's diranersen — an injectable therapy that targets toxic tau tangles in the brain — slowed cognitive decline by 26 to 50 percent across multiple clinical assessments, offering the first human proof that clearing tau alone can meaningfully alter the course of Alzheimer's disease.

• In the Phase 2 CELIA trial, the 60 mg dose of diranersen slowed clinical decline by 26% on the CDR-SB scale, 42% on the ADAS-Cog13 cognitive assessment, and 50% on the MMSE, compared to placebo over 18 months.
• Diranersen is an antisense oligonucleotide (ASO) administered via intrathecal injection every six months. It works by binding to tau mRNA and preventing the production of tau protein, thereby reducing the accumulation of neurofibrillary tangles that correlate with neurodegeneration.
• Biogen has announced plans to advance diranersen into Phase 3 trials. If confirmed, this would be the first Alzheimer's therapy targeting tau — rather than amyloid-beta — to demonstrate clinical benefit, opening an entirely new treatment axis.

For decades, the dominant hypothesis in Alzheimer's research has centered on amyloid-beta plaques — sticky protein clumps that accumulate between neurons. Drugs such as Leqembi (lecanemab) and Kisunla (donanemab) target amyloid and slow decline by roughly 25 to 35 percent in early-stage patients. But amyloid is only half the story. The other hallmark of Alzheimer's pathology is the tau protein, which forms twisted tangles inside neurons and correlates far more closely with the actual pattern and severity of cognitive symptoms.

The CELIA trial, conducted across 46 sites in North America and Europe, enrolled 230 participants with early-stage Alzheimer's disease confirmed by both amyloid and tau biomarkers. Patients were randomized to receive one of three dose levels of diranersen (30 mg, 60 mg, or 110 mg) or a placebo via lumbar puncture every 24 weeks. The results, presented on July 14 at AAIC 2026, showed that the 60 mg dose hit the primary endpoint — slowing clinical decline on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) by 0.54 points, a 26 percent reduction relative to placebo.

More striking were the secondary outcomes. On the Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13), diranersen slowed decline by 42 percent. On the Mini-Mental State Examination (MMSE), the benefit reached 50 percent. Cerebrospinal fluid analysis confirmed a dramatic, dose-dependent drop in both total tau and phosphorylated tau-217 — two key biomarkers — suggesting the drug was engaging its target as designed.

"This is the first time a tau-targeting therapy has demonstrated this magnitude of clinical effect in a randomized trial," said Dr. Maria Carrillo, Chief Science Officer of the Alzheimer's Association, in a statement accompanying the data release. "The field has been waiting for a tau win, and these results provide the clearest signal yet that tau is a viable therapeutic target."

The safety profile was manageable: the most common adverse events were transient headache and back pain following lumbar puncture, with no cases of ARIA (amyloid-related imaging abnormalities) that complicate amyloid-targeting therapies. Biogen confirmed it would meet with regulators to discuss the Phase 3 program expected to begin enrollment in early 2027.

For patients and families, the implications extend beyond a single drug. If tau modification works independently of amyloid clearance, combination therapy — attacking both proteins simultaneously — could produce additive or even synergistic benefits, pushing the field closer to what patients need: a treatment that stops the disease rather than merely slowing it.